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Abstract
Background: There is strong evidence of reductions in major vascular events from statins across all cardiovascular
risk categories. However, trials of statin therapy have provided conflicting results regarding statin use and type 2
diabetes (T2DM). We aimed to assess the effect of statins on T2DM development.
Method: We carried out a population-based cohort study using the Clinical Practice Research Datalink (CPRD), a
database of computerized clinical records. Every patient aged 30–85 years old starting a statin between 1989 and
2009 was matched with up to five non-statin users. The observation period in CPRD ended in 31 December 2011.
Cox proportional hazard regression was used to compare rates of T2DM between statin users and non-users, using
propensity score method to adjust for systematic differences between groups.
Results: The study basis comprised 2,016,094 individuals, including 430,890 people who received a statin, matched
to 1,585,204 people not prescribed a statin. Mean follow-up time was 5.43 years for statin users and 3.89 years for
nonusers. During follow-up 130,395 individuals developed T2DM. Statin use was associated with an increased risk of
T2DM (HR 1.57; 95% CI 1.54-1.59), which increases with longer duration of use. The increased risk was smaller
among people with hypertension or cardiovascular disease and was only apparent after 5 or more years treatment
with statins in these groups. Conversely, age-specific risk ratios decreased in older people.
Conclusions: Statin use is associated with an increased risk of T2DM. Our results suggest that the relative risk is
higher among people without diagnosed hypertension or cardiovascular disease. These findings should be
considered in the context of the observational nature of the data which is prone to bias and unmeasured
confounding.
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Background
Cardiovascular diseases (CVD) are the leading cause of
premature death and a major cause of morbidity worldwide
[1]. Reducing high blood cholesterol, a risk factor for
CVD events, is recommended as part of the global risk
management strategy for CVD prevention, with statins
being widely used as first-choice lipid-lowering therapy
after health behaviour interventions [2]. There is strong
evidence of reductions in major vascular events from
statins across all risk categories, from secondary prevention
to those at moderate and low risk of vascular events in
primary prevention [3-6].
Recently, two meta-analyses have raised concerns
regarding the potential risk for developing type 2 dia-
betes (T2DM) during statin use (odds ratio 1.09; 95%
CI 1.02-1.17 and odds ratio 1.09; 95% CI 1.02-1.16, respect-
ively) [7,8]. The first study (West of Scotland Coronary
Prevention Study [WOSCOPS]) that evaluated this out-
come reported a protective effect (hazard ratio 0.70; 95%
CI 0.50-0.98) but used no standardized criteria for T2DM
diagnosis [9]. The increase in T2DM relative risk of 25%
over a mean follow up of 1.9 years (hazard ratio 1.25; 95%
CI 1.05-1.54) among participants in the JUPITER trial of
the role of rosuvastatin in primary prevention reignited
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concern about this association [10]. Other studies have
provided conflicting results regarding statin use and
T2DM, including a nested case–control study using
data from the UK General Practice Research Database
(GPRD) that reported no strong evidence of a harmful
effect of statins on the development of T2DM [11-13]. New
analyses using data from the Women's Health Initiative
(WHI) study suggest that the risk of T2DM among elderly
women who reported statin use at baseline and at year 3
follow-up is higher than that observed in previous studies
(HR = 1.47; 95% CI 1.32-1.64) [14]. In the Taiwan National
Health Insurance Research Database, statin use increased
the hazards of diabetes occurrence by 15% (HR 1.15; 95%
CI 1.08 - 1.22) [15]. Furthermore, it appears that the risk of
statin-induced diabetes is higher with intensive-dose statin
therapy and among elderly people [6,16]. In Ontario Drug
Benefit database patients treated with atorvastatin were
found to have a 22% increased risk of new-onset diabetes,
rosuvastatin an 18% increased risk and simvastatin a 10%
increased risk, relative to pravastatin (reference group) [17].
The risk of developing diabetes on statins is strongly associ-
ated with baseline fasting blood glucose and with the num-
ber of co-existing CVD risk factors, suggesting that statins
raise blood glucose by a small amount, moving people from
below to above the diagnostic threshold [18]. However, a
definitive mechanism by which statins increase incident
diabetes has not yet been elucidated.
This issue raises new concerns on the benefit-risk ratio
of statins in low cardiovascular risk individuals. The under-
lying incidence rates for T2DM vary between populations
and have been rising rapidly worldwide over the past three
decades [19,20]. Since 1990 the rising prevalence of type 2
diabetes, combined with a constant relative risk for CVD,
has translated into a 60% increase in the attributable risk of
CVD associated with diabetes, even while the attributable
risk for CVD associated with other risk factors (hyperten-
sion and smoking) has held constant or fallen [21].
Quantifying the absolute effects of statins on T2DM is re-
quired to guide their clinical use. It is also necessary to de-
termine how the results from clinical trials compare with
what occurs in clinical practice, particularly among patients
who are older, have more comorbid conditions, or receive
higher statin doses than most patients in clinical trials.
Therefore, use of large-scale observational data from rou-
tine medical practice to study the association between statin
use and risk of T2DM is helpful in testing the hypothesis
further. We therefore aimed to undertake a population-
based cohort study based on computerized medical records
derived from primary care in the UK to compare the rates
of incident T2DM between users and non-users of statins.
Method
We carried out a population-based retrospective cohort
study using the Clinical Practice Research Datalink (CPRD).
Ethics statement
This study was approved by the London School of
Hygiene and Tropical Medicine Ethics Committee (appli-
cation ref. 6081).
Clinical practice research datalink
The Clinical Practice Research Datalink is a collection of
anonymised longitudinal electronic health records from
primary care in the United Kingdom (UK) hosted by
the UK Medicines and Healthcare products Regulatory
Agency’s (MHRA). All the data from patients is anon-
ymised and no personal details are shared with health
researchers. Data collection started in 1987. It includes
diagnostic and prescribing information, as well as in-
formation on various lifestyle characteristics for more
than 11 million patients from more than 600 general
practices. The database is broadly representative of the
UK population [22] and several studies have confirmed
the validity of the diagnostic and prescription data in the
CPRD for pharmacoepidemiological research [23-27].
Participants
The source population was all patients registered with a
general practice between January 1989 (statins were avail-
able from around this time and the database was started
in 1987) and December 2009. Within this time period,
study start dates were derived from the latest of the date
the practice began contributing research quality data
(CPRD defined quality marker based on assessment of
completeness, continuity and plausibility of data recording
in key areas) or the patient’s first registration date. Study
end dates were derived using the earlier of the patient’s
transfer out date or the practice’s last collection date.
We included in the study all patients aged 30–85 years
old who received their first prescription for a statin on
or after 1st January 1989 up until 31st December 2009,
after at least 12 months registration in the CPRD to
avoid including people who had been initiated on statin
therapy prior to inclusion in the CPRD. For this study,
the observation period in CPRD ended in 31 December
2011. Statin use was defined as at least one prescription
during the study period and the date of first statin pre-
scription was termed the index date. Then, we matched
up to five non-statin users to each statin user on sex,
general practice, age (+/− 2.5 years) and being registered
in the CPRD on the index date of the statin user and for at
least 12 months previously. Matching on general practice
and index date helps reduce confounding by time period
and by practice specific factors that might be difficult to
measure or control for.
The index date for non-users was set as the index date
for their matched statin user. Non-users also had to have
no record of a statin prescription before the index date,
but could be prescribed a statin later, in order to avoid
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selecting a biased control group who were not at risk of
being prescribed a statin. We required both users and
non-users of statins to have had some form of contact
recorded with the practice within 12 months before and
after the index date, in order to ensure all participants
were active within their general practices. To avoid
immortal time bias, we also took into account the time
during which the outcome couldn’t occur for statin
users. So, we included the period of time between cohort
entry (study start dates) and the day before starting a
statin in the pool of non-users that were matched with
the users.
Patients were excluded from the study if they had a
diagnosis of T2DM or T1DM at or before the index date.
Pregnant women (10 months before the index date) or
with gestational DM history were also excluded.
Incident T2DM diagnoses were ascertained from the
CPRD record using Read codes (Additional file 1: list S1)
and the date of diagnosis was determined by the earliest
date of any recorded T2DM code. We censored follow-up
at the earliest date of the diagnosis of T2DM, death from
any cause, end of observation period in the CPRD or the
date the study ended (31 December 2011).
Analysis
Propensity score
In clinical practice exposure to statins is not randomized
but is determined by a wide range of health-related fac-
tors. Systematic differences between statin users and
non-users can bias the estimated exposure effect. Propen-
sity scores (PS) can be used to adjust for the conditional
probability of being prescribed a statin, given a set of
chosen covariates. PS were estimated using conditional lo-
gistic regression, with statin prescription at the index date
as the outcome. Variables were selected for inclusion
in the PS model if they were associated with both the
exposure and the outcome, or associated with the out-
come only [28]: hyperlipidaemia, hypertension, abnor-
mal glucose levels, smoking and drinking habits, family
history of diabetes, family history of CVD, consultation
rate (defined as the number of times a patient initiated
contact with a general practice in the 12 months prior to
the index date), prescribing rate (defined as the number of
prescriptions in the 12 months prior to the index date),
cardiovascular disease (including coronary heart disease,
cerebrovascular disease and peripheral vascular disease),
other unspecified atheroma, atrial fibrillation, heart failure,
cancer, osteoporosis, recent hepatic or renal disease (within
6 months), thyroid disease, recent use of non-statin
lipid-lowering medication (within 3 months), hormone
replacement therapy (within 1 year), antidepressants (within
6 months), atypical antipsychotics (within 6 months), oral
or inhaled glucocorticoids (within 6 months), bisphospho-
nates (within 1 year), cytochrome P450 3A4 inhibitors
(within 3 months); and any previous use of cardiovas-
cular drugs (including β-blockers, diuretics, calcium
antagonists, angiotensin converting enzyme inhibitors,
angiotensin receptor blockers, aspirin, anticoagulants,
digoxin and nitrates).
We examined the distributions of PS in both exposure
groups to ensure that only patients with overlapping scores
were included. Patients with scores in the extreme upper
and lower tail of the PS distribution (outside the 5th to the
95th percentiles) were excluded, as the inclusion of people
treated contrary to extreme scores can introduce bias from
unmeasured confounding [29]. Sensitivity analyses were
conducted without this exclusion.
Statistical analysis
All data management and statistical analysis were per-
formed using STATA software.
In the primary analysis, Cox proportional hazard re-
gression was used to compare rates of T2DM between
statin users and non-users. Hazard ratios (HR) and 95%
confidence intervals were estimated for statins initiated
at index date, analogous to an intention to treat analysis.
The initial model was adjusted for age, sex, family history
of diabetes, post-index date new diagnosis of hepatic dis-
ease and propensity score categories. Further adjustment
for sex, family history of diabetes and post-index date new
diagnosis of hepatic disease did not affect the results, so
these factors were not included. The final model included
propensity score and further adjustment for age only.
Several sensitivity analyses were then carried out. First,
we assessed the effect of censoring observation periods for
each individual at the time they stopped taking statins and
at the time their exposure status changed: when subjects
changed their statin dose and/or switched to another
statin and/or received another lipid-lowering drug in
addition to the statin; or when subjects in the unexposed
group were prescribed a statin. The date of stopping statins
was assumed as 90 days after the date of the last recorded
prescription. Secondly, we restricted the analysis to the first
6 months of exposure, since a positive association over a
short exposure duration could indicate a possible bias.
Missing data were quantified for each variable and classi-
fied as “unknown” category. For the majority of variables
data was considered to be missing at random, so the main
analyses didn’t exclude patients with missing data for any
of the confounding variables. When the nature or the ex-
tent of missingness was considered important (e.g. BMI)
we conducted a sensitivity analysis restricted to patients
with low or normal BMI levels to explore its impact on
the results.
As secondary analyses, to assess the possible effect
modification of variables related to both the exposure
and the outcome, we repeated the analyses stratified on
age groups, body mass index (BMI) categories, baseline
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diagnoses of hypertension and CVD (including coronary
heart disease, cerebrovascular disease and peripheral
vascular disease), and duration of use (1 year, 1–3 years,
3–5 years, 5–10 years, 10–15 years, 15–20 years and
20–25 years).
Results
The study basis comprised 2,016,094 individuals, including
430,890 people who received a statin, matched to 1,585,204
people not prescribed a statin (an average of 3.8 non-users
per user). Mean follow-up time was 5.43 years (SD 3.08;
maximum 21.76 years) for statin users and 3.89 years (SD
2.56; maximum 21.75 years) for nonusers.
Table 1 shows the baseline characteristics of statin users
and non-users. Men and women were approximately
equally represented. Compared with non-users of statins,
new users tended to be older, were more overweight
(67.51% with BMI > 25Kg/m2) and were more likely to
have comorbidities, mainly hypertension and cardio-
vascular disease. They were also more likely to have
had some form of contact with their practices and
some drug prescription in the 12 months prior to the
index date, as shown by their higher annual consultation
and prescription rates. There were some missing data on
smoking status (4.0%), alcohol consumption (11.7%), and
BMI (12.5%).
Of the new statin users, 271,126 (62.92%) had been
prescribed simvastatin; 111,734 (25.93%) atorvastatin;
25,881 (6.00%) pravastatin; 15,380 (3.57%) rosuvastatin
and 5,963 (1.38%) fluvastatin (Table 2). Additionally, 720
(0.17%) individuals were prescribed simvastatin with eze-
tibime and 86 (0.02%) received a statin and another lipid
lowering drug.
During follow-up 130,395 individuals developed T2DM,
56,702 cases among statin users and 73,693 among non
users. Patients who developed T2DM were older, were
more overweight (78.22% with BMI > 25Kg/m2) and were
more likely to have comorbidities, mainly hypertension
and cardiovascular disease (Table 2). The severity of
T2DM, measured by the type of treatment used, differed
by statin exposure status: six months after T2DM diagno-
sis 41,210 patients (21.40% users vs. 39.95% non users)
were being prescribed oral anti-diabetic drugs (OAD) and
4,439 patients (0.25% users and 4.55% non users) were be-
ing prescribed a combination of OAD and insulin. The
remaining 84,746 patients (77.34% users and 55.49%
non users) with T2DM were not being prescribed any
hypoglycemic medicine 6 months after diagnosis.
Table 3 shows the crude incidence of T2DM per 1000
person-years by statin exposure status, crude and adjusted
hazard ratios. Hazard ratios were increased in crude, ad-
justed and fully adjusted models with little attenuation;
after adjustment for age and propensity score (final
model) statin use was associated with an increased risk
of T2DM (HR 1.57; 95% CI 1.54-1.59). In this primary
analysis restricted to the 5th-95th percentile of PS dis-
tribution the cohort consisted of 1,448,993 individuals,
of whom 386,746 were users and 1,062,247 nonusers.
The sensitivity analysis conducted without this restriction
gave similar results. The hazard ratios were higher in the
first 6 months of exposure.
During the observation period, 14.46% (n = 62,301)
of the exposed group stopped statin therapy and 8.43%
(n = 169,900) of the participants changed their treatment.
The re-analysis censoring observation periods at the time
of stopping statin exposure or changing treatment found
small increases in rates, particularly in the exposed group,
with consequently higher hazard ratios.
To assess the possible effect modification of variables
related to both the exposure and the outcome, we repeated
the analyses stratified by age groups, BMI categories,
hypertension and CVD diagnoses, and duration of statin
use (Table 4). The stratified analysis found increased risks
of T2DM associated with higher BMI levels and longer
follow-up. Conversely, age-specific risk ratios decreased in
older people, even though an association was observed in
all strata. Incidence rates of T2DM increase with age in
non-statin users, whereas in statin users incidence rates
were higher and did not show an age gradient.
There was only a small increased risk of T2DM associ-
ated with statin exposure among people with diagnosed
hypertension at baseline (HR 1.04; 95% CI 1.01-1.07); and
there was evidence of a protective effect in people with di-
agnosed CVD at baseline (HR 0.86; 95% CI 0.82-0.89). To
explore further this effect modification we stratified the
analysis for these groups according to different follow-up
times and calculated the median time for T2DM diagnosis
in each time band (Table 5). The time varying analysis
confirmed that the highest risk observed in the first year
of starting treatment could be due to a detection bias,
since among statin users 50% of T2DM diagnoses were
done 139 days (4.5 months) after starting treatment, com-
pared to 210 days (7 months) for the nonusers. This bias
doesn’t seem to continue throughout statin use since no
significant differences were observed in the other time pe-
riods. An increased hazard of T2DM among statin users
was apparent from the first year among people without
hypertension or CVD but in people with these conditions
an increased hazard of T2DM was apparent by 5 years
of use. In a sensitivity analysis to explore the impact of
exposure status changing during follow-up we re-ran
the analysis censoring observation periods at the time of
stopping statin exposure or changing treatment. This
showed no differences in risk estimates (Additional file 1:
Table S1). Since diabetes, hypertension and CVD share
similar underlying risk factors, we also compared the pro-
portions of some baseline predictors of new-onset T2DM
for hypertensive and CVD patients, according to their
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exposure status (Additional file 1: Table S2). No significant
differences were observed according to exposure status.
In all groups the majority of individuals were overweight
or obese and a large proportion of CVD patients were
hypertensive (33.98% in exposed vs. 50.58% in unexposed),
indicating an overlap among the CVD and hypertension
groups.
To examine whether the lower and protective hazard
ratios observed in patients with hypertension and CVD
were due to their high BMI levels we repeated the ana-
lysis for these groups, including only patients with
BMI ≤ 25Kg/m2 (underweight/normal) (Additional file 1:
Table S3). The observed rates of T2DM across the ex-
posed groups were similar among both hypertensives and
non-hypertensives and among the CVD and no-CVD
groups with increased incidence of T2DM occurring from
3–5 years of exposure and consistently increased hazard
ratios after 5 years of use. These findings suggest that
in non-overweight people long-term statin use may
also increase occurrence of T2DM.
Discussion
This study examined and quantified the risk of diabetes
associated with statin use in a large representative primary
care population over more than 20 years. We found an in-
creased risk of T2DM associated with statin use, which
Table 1 Baseline characteristics of study population of
new users and non-users of statins
Exposed (new users) Unexposed
Baseline characteristics n (%) n (%)
All patients (n = 2,016,094) 430,890 (21.37) 1,585,204 (78.63)
Gender
Male 231,732 (53.78) 835,053 (52.68)
Female 199,158 (46.22) 750,151 (47.32)
Age mean (sd), yrs 63.77 (10.81) 61.86 (11.27)
30-39 7,584 (1.76) 37,221 (2.35)
40-49 37,386 (8.68) 183,876 (11.60)
50-59 100,079 (23.23) 455,649 (28.74)
60-69 146,431 (33.98) 490,132 (30.92)
70-79 109,894 (25.50) 311,974 (19.68)
80-85 29,516 (6.85) 106,352 (6.71)
BMI, kg/m2
<20 11,223 (2.60) 65,496 (4.13)
20-25 107,711 (25.00) 457,240 (28.84)
>25 290,876 (67.51) 831,395 (52.45)
Unknown 21,080 (4.89) 231,073 (14.58)
Smoking status
Current smokers 90,670 (21.04) 266,333 (16.80)
Former smoker 163,576 (37.96) 532,087 (33.57)
Non-smoker/never 175,360 (40.70) 706,908 (44.59)
Unknown status 1,284 (0.30) 79,876 (5.04)
Alcohol use
Current (unknown amount) 21,009 (4.88) 43,762 (2.76)
Rare drinker (<2u/d) 63,213 (14.67) 229,758 (14.49)
Moderate drinker (3-6u/d) 223,242 (51.81) 757,940 (47.81)
Excessive drinker (>6u/d) 40,912 (9.49) 135,790 (8.57)
Past use 8,130 (1.89) 40,337 (2.54)
Non-drinker 53,566 (12.43) 161,639 (10.20)
Unknown status 20,818 (4.83) 215,978 (13.62)
Family history of:
Diabetes 17,914 (4.16) 55,962 (3.53)
Cardiovascular disease 113,104 (26.25) 307,406 (19.39)
Diagnosis of:
Hyperlipidaemia 29,140 (6.76) 30,277 (1.91)
Atherosclerosis 1,664 (0.39) 2,175 (0.14)
Hypertension 176,946 (41.07) 352,371 (22.23)
Heart failure 10,448 (2.42) 20,160 (1.27)
Cardiovascular disease 98,739 (22.92) 101,666 (6.41)
Atrial fibrillation 17,907 (4.16) 36,005 (2.27)
Hepatic disease
(within 6 months)
1,808 (0.42) 5,736 (0.36)
Kidney disease
(within 6 months)
13,813 (3.21) 27,352 (1.73)
Table 1 Baseline characteristics of study population of
new users and non-users of statins (Continued)
Abnormal glucose level 6,076 (1.41) 11,757 (0.74)
Osteoporosis 13,047 (3.03) 45,262 (2.86)
Cancer 42,929 (9.96) 159,664 (10.07)
Thyroid disease 34,863 (8.09) 105,555 (6.66)
Prior use of:
Antipsychotics
(within 6 months)
252 ( 0.06) 1,317 (0.08)
Antidepressants
(within 6 months)
5,876 (1.36) 15,495 (0.98)
Cardiovascular drugs 124,687 (28.94) 608,423 (38.38)
Nonstatin lipid lowerers
(within 3 months)
894 (0.21) 336 (0.02)
Systemic glucocorticoids
(within 6 months)
5,617 (1.30) 14,354 (0.91)
Oestrogens/HRT
(within 1 year)
3,222 (0.75) 6,265 (0.40)
Bisphosphonates
(within 1 year)
2,310 (0.54) 10,154 (0.64)
CYP450 3A4 inhibitor 6,962 (1.62) 13,363 (0.84)
Annual consultation rate,
mean (SD)
25.99 (18.56) 15.76 (17.42)
Annual prescription rate,
mean (SD)
25.80 (31.69) 8.34 (21.02)
All the differences between groups were significant at the 0.05 level (two-sided).
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increases with longer duration of use and higher baseline
BMI levels, and decreases with age. The size of the in-
creased risk was smaller among people with diagnosed
hypertension or cardiovascular disease and was only evi-
dent after 5 or more years treatment in these groups.
Our findings confirm those from randomized trials
where an increased risk of diabetes was found in both
primary and secondary prevention (OR 1.18; 95% CI
1.01-1.39 and OR = 1.09; 95% CI 1.02-1.17 respectively)
[7,29]. The Cholesterol Treatment Trialist Collaborators
did not include diabetes among the adverse effects stud-
ied. Recently, one prospective cohort study of large sample
size (Women’s Health Initiative) found evidence of an
increased risk of T2DM (HR = 1.47; 95% CI 1.32-1.64) for
the groups of women who reported statin use at baseline
and at year 3 follow-up [14] This observational study,
in common with our study, found a much stronger as-
sociation than those found in clinical trials.
Our results also suggest an apparent effect modification
by hypertension and CVD in the risk of T2DM associated
with statin use. The baseline risk of T2DM observed in
these groups (around 20 per 1000 person-years) is similar
to the rates found in other studies [30,31] Statins do not
seem to have any additional effect on this baseline risk of
T2DM in the first years of treatment. After 5 years, statin
use was associated with an increased risk of T2DM.
Several studies have demonstrated that persons with
hypertension are at significantly elevated risk of developing
Type 2 diabetes [31-35]. These studies have shown a close
association between insulin resistance and hypertension,
Table 2 Baseline characteristics of patients who
developed T2DM
Baseline characteristics Subjects with
incident T2DM
Subjects without
incident T2DM
n (%) n (%)
All patients (n = 2,016,094) 130,395 (6.47) 1,885,699 (93.53)
Gender
Male 70,972 (54.43) 995,813 (52.81)
Female 59,423 (45.57) 889,886 (47.19)
Age mean (sd), yrs 63.44 (10.54) 62.19 (11.24)
30-39 1,697 (1.30) 43,108 (2.29)
40-49 11,324 (8.68) 209,938 (11.13)
50-59 33,703 (25.85) 522,025 (27.68)
60-69 43,636 (33.46) 592,927 (31.44)
70-79 32,174 (24.67) 389,694 (20.67)
80-85 7,861 (6.03) 128,007 (6.79)
BMI, kg/m2
<20 2,461 (1.89) 74,258 (3.94)
20-25 20,947 (16.06) 544,004 (28.85)
>25 102,001 (78.22) 1,020,270 (54.11)
Unknown 4,986 (3.82) 247,167 (13.11)
Smoking status
Current smokers 21,742 (16.67) 335,261 (17.78)
Former smoker 59,403 (45.56) 636,260 (33.74)
Non-smoker/never 48,775 (37.41) 833,493 (44.20)
Unknown status 475 (0.36) 80,685 (4.28)
Alcohol use
Current (unknown amount) 5,044 (3.87) 59,727 (3.17)
Rare drinker (<2u/d) 21,939 (16.83) 271,032 (14.37)
Moderate drinker (3-6u/d) 64,639 (49.57) 916,543 (48.60)
Excessive drinker (>6u/d) 40,912 (9.49) 135,790 (8.57)
Past use 4,200 (3.22) 44,267 (2.35)
Non-drinker 17,844 (13.68) 197,361 (10.47)
Unknown status 5,809 (4.45) 230,987 (12.25)
Family history of:
Diabetes 6,607 (5.07) 67,269 (3.57)
Cardiovascular disease 29,012 (22.25) 391,498 (20.76)
Diagnosis of:
Hyperlipidaemia 6,372 (4.89) 53,045 (2.81)
Atherosclerosis 373 (0.29) 3.466 (0.18)
Hypertension 50,529 (38.75) 478,788 (25.39)
Heart failure 3,235 (2.48) 27,373 (1.45)
Cardiovascular disease 20,852 (15.99) 179,553 (9.52)
Atrial fibrillation 5,117 (3.92) 48,795 (2.59)
Hepatic disease (within 6 months) 787 (0.60) 6,757 (0.36)
Kidney disease (within 6 months) 2,671 (2.05) 38,494 (2.04)
Abnormal glucose level 3,780 (2.90) 14,053 (0.75)
Table 2 Baseline characteristics of patients who
developed T2DM (Continued)
Osteoporosis 3,099 (2.38) 55,210 (2.93)
Cancer 12,916 (9.91) 189,677 (10.06)
Thyroid disease 10,747 (8.24) 129,671 (6.88)
Prior use of:
Antipsychotics (within 6 months) 114 ( 0.09) 1,455 (0.08)
Antidepressants (within 6 months) 1,503 (1.15) 19,868 (1.05)
Cardiovascular drugs 53,096 (40.72) 680,014 (36.06)
Nonstatin lipid lowerers
(within 3 months)
189 (0.14) 1,041 (0.06)
Systemic glucocorticoids
(within 6 months)
1,496 (1.15) 18,475 (0.98)
Oestrogens/HRT (within 1 year) 706 (0.54) 8,781 (0.47)
Bisphosphonates 699 (0.54) 11,765 (0.62)
CYP450 3A4 inhibitor 1,709 (1.31) 18,616 (0.99)
Annual consultation rate,
mean (SD)
22.16 (19.33) 17.66 (18.04)
Annual prescription rate,
mean (SD)
19.42 (30.12) 11.57 (24.27)
All the differences between groups were significant at the 0.05 level (two-sided).
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Table 3 Incidence rates of T2DM by statin exposure status and crude and adjusted hazard ratios
Nº of
subjects
Incident T2DM per 1000 person-years (95% CI) Hazard ratio
(95% CI)
crude
Hazard ratio
(95% CI) fully
adjusted*
Hazard ratio (95% CI)
adjusted for age and
propensity score**
Exposed Unexposed
All sample 2,016,094 24.24 (24.04-24.44) 11.95 (11.86-12.04) 1.99 (1.97-2.01) 1.57 (1.54-1.59) 1.57 (1.55-1.60)
PS [5-95%] 1,448,993 23.90 (23.69-24.11) 12.2 (12.01-12.31) 1.91 (1.89-1.94) 1.56 (1.54-1.59) 1.57 (1.54-1.59)
Stop 2,016,094 25.32 (25.71-26.14) 11.95 (11.86-12.04) 2.13 (2.11-2.16) 1.70 (1.67-1.72) 1.71 (1.68-1.73)
1,448,993 25.54 (25.32-25.77) 12.20 (12.10-12.31) 2.05 (2.02-2.07) 1.69 (1.66-1.71) 1.70 (1.67-1.72)
Change 2,016,094 29.38 (29.14-29.63) 12.13 (12.04-12.21) 2.42 (2.40-2.45) 1.90 (1.87-1.93) 1.91 (1.88-1.93)
1,448,993 28.98 (28.73-29.24) 12.39 (12.28-12.50) 2.33 (2.31-2.36) 1.90 (1.87-1.93) 1.91 (1.88-1.94)
First 2,016,094 23.80 (23.15-24.47) 9.69 (9.48-9.91) 2.45 (2.37-2.54) 2.15 (2.05-2.25) 2.14 (2.05-2.25)
6 months 1,448,993 23.92 (23.23-24.62) 9.86 (9.59-10.13) 2.43 (2.33-2.52) 2.18 (2.08-2.29) 2.18 (2.07-2.29)
After 2,003,499 24.28 (24.07-24.89) 12.28 (12.37-24.49) 1.95 (1.92-1.97) 1.51 (1.49-1.54) 1.52 (1.49-1.54)
6 month 1,436,377 23.89 (23.68-24.11) 12.54 (12.43-12.66) 1.86 (1.84-1.89) 1.50 (1.47-1.53) 1.51 (1.48-1.53)
PS – propensity score; Stop – observation periods censored at time of statin withdrawn Change – observation periods censored at time exposure status changed.
All the variables in Table 1 were included in propensity score model. *Full model: adjusted for age, gender, propensity score, post index date diagnosis of hepatic
disease and family history of diabetes. **Final model: adjusted for age and propensity score.
Table 4 Risk of T2DM by statin use, stratified by age groups, BMI categories, hypertension, CVD and follow-up time
PS [5-95%] Incident T2DM per 1000 person-years (95% CI) Hazard ratio (95% CI) adjusted
for age and propensity score(N = 1,448,993) Exposed Unexposed
Age
30-39 23.16 (21.70-24.72) 3.89 (3.59-4.21) 4.68 (4.12-5.31)
40-49 25.13 (24.43-25.84) 6.70 (6.80-7.20) 2.84 (2.70-2.99)
50-59 25.22 (24.79-25.65) 10.83 (10.65-11.00) 1.87 (1.82-1.93)
60-69 23.88 (23.52-24.23) 14.53 (14.31-14.75) 1.34 (1.30-1.37)
70-79 22.94 (22.52-23.36) 17.81 (17.49-18.14) 1.15 (1.11-1.19)
80-85 20.30 (19.48-21.15) 13.83 (13.32-14.36) 1.25 (1.17-1.34)
BMI, kg/m2
<20 11.71 (10.79-12.70) 6.76 (6.38-7.15) 1.20 (1.06-1.36)
20-25 13.22 (12.92-13.53) 6.54 (6.41-6.67) 1.51 (1.45-1.57)
>25 28.99 (28.72-29.75) 17.18 (17.01-17.35) 1.40 (1.38-1.43)
Hypertension 26.41 (26.06-26.77) 21.80 (21.49-22.12) 1.04 (1.01-1.07)
No hypertension 22.32 (22.06-22.57) 9.69 (9.58-9.80) 1.92 (1.88-1.95)
CVD 23.42 (23.00-23.85) 21.91 (21.32-22.53) 0.86 (0.82-0.89)
No CVD 24.04 (23.80-24.28) 11.63 (11.53-11.74) 1.70 (1.67-1.72)
Follow up time (years)
0-1 yr 19.97 (19.52-20.42) 11.53 (11.33-11.74) 1.52 (1.47-1.57)
1-3 yr 20.11 (19.77-20.44) 13.55 (13.37-13.74) 1.22 (1.19-1.25)
3-5 yr 24.56 (24.12-25.00) 11.61 (11.38-11.84) 1.73 (1.68-1.80)
5-10 yr 30.04 (29.55-30.53) 10.85 (10.59-11.12) 2.25 (2.17-2.34)
10-15 yr 34.93 (33.52-36.39) 10.20 (9.38-11.10) 3.05 (2.71-3.43)
15-20 yr 42.24 (36.90-48.36) 12.24 (9.08-16.51) 3.63 (2.44-5.38)
20-25 yr 13.10 (1.84-93.00) n.e. n.e.
n.e - no estimation.
Macedo et al. BMC Cardiovascular Disorders 2014, 14:85 Page 7 of 12
http://www.biomedcentral.com/1471-2261/14/85
Table 5 Incident rates and median time for T2DM diagnosis at different follow-up times, according to hypertension
and CVD diagnosis
Statin use
Yes No
Follow up time (years) PS
[5-95%] (N = 1,448,993)
Hazard ratio
(95% CI)*
Incident T2DM per 1000
person-years (95% CI)
Nº T2DM /Median
time (days)
Incident T2DM per 1000
person-years (95% CI)
Nº T2DM /Median
time (days)
Total sample
0-1 yr 1.52 (1.47-1.57) 19.97 (19.52-20.42) 7,634/139 11.53 (11.33-11.74) 12,189/210
1-3 yr 1.22 (1.19-1.25) 20.11 (19.78-20.44) 13,786/727 13.35 (13.34-13.37) 21,418/644
3-5 yr 1.73 (1.68-1.80) 24.56 (24.12-25.00) 11,858/1,440 11.61 (11.38-11.84) 9,773/1,394
5-10 yr 2.25 (2.17-2.34) 30.03 (29.55-30.53) 14,523/2,450 10.85 (10.59-11.12) 6,534/2,312
10-15 yr 3.05 (2.71-3.43) 34.93 (33.53-36.39) 2,292/4,174 10.20 (9.38-11.10) 543/4,166
15-20 yr 3.63 (2.44-5.38) 42.24 (36.90-48.36) 210/5,877 12.24 (9.10-16.51) 43/5,773
20-25 yr n.e. 13.10 (1.84-93.00) 1/ - 0 0/ -
No hypertension
0-1 yr 2.05 (1.96-2.15) 19.53 (18.97-20.11) 4,486/134 8.65 (8.44-8.85) 6,893/215
1-3 yr 1.50 (1.45-1.55) 18.64 (18.23-19.06) 7,694/727 10.60 (10.42-10.77) 13,114/653
3-5 yr 2.00 (1.92-2.09) 22.15 (21.61-22.69) 6,463/1,439 9.56 (9.33-9.80) 6,550/1,400
5-10 yr 2.50 (2.39-2.61) 27.65 (27.06-28.24) 8,502/2,482 9.32 (9.06-9.59) 4,750/2,335
10-15 yr 3.14 (2.75-3.58) 32.86 (31.26-34.55) 1,541/4,180 9.31 (8.48-10.21) 446/4,186
15-20 yr 3.84 (2.52-5.86) 41.61 (35.64-48.59) 160/5,877 11.55 (8.41-15.88) 38/5,780
20-25 yr n.e. 0 0/ - 0 0/ -
Hypertension
0-1 yr 0.96 (0.91-1.01) 20.62 (19.91-21.35) 3,148/145 20.40 (19.86-20.96) 5,296/204
1-3 yr 0.84 (0.81-0.88) 22.33 (21.77-22.89) 6,092/726 24.20 (23.68-24.72) 8,304/625
3-5 yr 1.22 (1.15-1.29) 28.24 (27.50-29.00) 5,395/1,442 20.51 (19.82-21.23) 3,223/1,380
5-10 yr 1.56 (1.46-1.67) 34.22 (33.37-35.10) 6,021/2,405 19.25 (18.38-20.17) 1,784/2,264
10-15 yr 2.19 (1.68-2.84) 40.09 (37.32-43.06) 751/4,156 18.33 (15.02-22.37) 97/4,073
15-20 yr 2.32 (0.77-7.01) 44.38 (33.64-58.56) 50/5,876 22.38 (9.31-53.77) 5/ -
20-25 yr n.e. 0 0/ - 0 0/ -
No CVD
0-1 yr 1.74 (1.67-1.80) 20.72 (20.22-21.24) 6,260/136 10.74 (10.54-10.95) 10,474/213
1-3 yr 1.31 (1.28-1.35) 20.37 (19.99-20.75) 11,037/725 12.93 (12.75-13.11) 19,254/647
3-5 yr 1.85 (1.78-1.92) 24.94 (24.44-25.45) 9,325/1,438 11.18 (10.95-11.42) 9,022/1,393
5-10 yr 2.34 (2.24-2.43) 30.44 (29.86-31.02) 10,512/2,416 10.56 (10.30-10.83) 6,134/2,317
10-15 yr 2.96 (2.61-3.35) 33.58 (31.85-35.97) 1,379/4,151 10.08 (9.26-10.99) 523/4,166
15-20 yr 3.76 (2.49-5.67) 41.78 (35.54-49.11) 147/5,985 11.81 (8.70-16.04) 41/5,773
20-25 yr n.e. 0 0/ - 0 0/ -
CVD
0-1 yr 0.75 (0.69-0.82) 17.11 (16.23-18.04) 1,374/147 21.05 (20.08-22.07) 1,715/196
1-3 yr 0.75 (0.70-0.80) 19.12 (18.42-19.85) 2,749/733 23.77 (22.79-24.79) 2,164/613
3-5 yr 0.97 (0.88-1.06) 23.24 (22.35-24.17) 2,533/1,445 21.30 (19.83-22.88) 751/1,408
5-10 yr 1.34 (1.19-1.50) 29.05 (28.16-29.96) 4,011/2,540 18.73 (16.98-20.66) 400/2,223
10-15 yr 2.26 (1.42-3.57) 37.19 (34.85-39.68) 913/4,224 14.70 (9.49-22.79) 20/4,204
15-20 yr 1.45 (0.31-6.74) 43.36 (33.87-55.08) 63/5,762 48.47 (12.12-193.81) 2/ -
20-25 yr n.e. 0 0/ - 0 0/ -
PS – propensity score; *Final model: adjusted for age and propensity score; n.e. – no estimation.
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although the question whether the insulin resistance leads
to hypertension or vice versa is not yet clear [36,37]. The
mechanism by which statins increase incident diabetes is
not known. In a systematic review and meta-analysis by
Baker and colleagues, statins as a class had no impact on
insulin sensitivity, though pravastatin increased insulin
sensitivity and simvastatin (lipophilic statin) worsened it
[38]. Statins may also directly affect insulin secretion via
the convergence of multiple mechanisms that comprom-
ise the integrity and function of β-cells [39-41]. Kruit and
colleagues have recently established a role between cell
cholesterol homeostasis and insulin secretion [41-43]. The
inhibition of HMG-CoA reductase upregulates the expres-
sion of LDL receptor in a time-dependent manner. In the
liver, this leads to increased cholesterol clearance in bile.
However, in peripheral tissues like pancreatic β-cells that
do not degrade cholesterol, enhanced LDL receptor ex-
pression could lead to increased cellular cholesterol and
impair insulin secretion [41-43]. A number of genes in-
volved in lipid metabolism have also been implicated in
T2DM, however further research is needed to extrapolate
the findings to humans [41,42].
Our observed differences in risk of T2DM in people
with or without hypertension or CVD in the first 5 years
of treatment is surprising. It is likely that people started
on statins and also diagnosed with hypertension and
CVD will also receive more life-style advice, in particular
increased physical activity, and may be more likely to ad-
here to advice. There is evidence that such interventions
reduce the risk of T2DM [44], but may not provide
long-term protection [45], which may explain our findings.
Over time, impaired insulin secretion induced by statins
worsens, more beta cells become unable to secrete suffi-
cient insulin to compensate for insulin resistance with
hyperinsulinemia, increasing the risk of developing Type 2
diabetes with longer statin use. This mechanism could
make hypertensive patients, already with insulin resist-
ance, develop T2DM faster than non-hypertensives, which
would explain the slightly higher rates of T2DM observed
in hypertensive statins users per time band, compared
with non-hypertensives users.
The hazard ratios observed in patients with hyper-
tension and CVD were not due to their high BMI levels
(as shown by our sensitivity analysis), although small
decreased rates of T2DM were found when the analysis
was restricted to patients with low BMI levels (under-
weight/normal). Obesity and overweight are strong pre-
dictors of T2DM, with profound impact on the disease
progression, often preceding the development of many
metabolic disorders characterized by insulin resistance, in-
cluding hypertension and CVD [46].
The age-specific risk ratios of T2DM decreased in
older people. In non statin-users the increase in T2DM
with age is expected probably due to age-dependent loss
of β-cells and increased obesity and reduced physical
activity. In statin users the T2DM rates were higher and
did not show an age gradient. There is a growing consen-
sus that one mechanism by which statins increase incident
diabetes is by pushing people over the diagnostic thresh-
old of blood glucose earlier than people with similar risk
factor profiles but not taking statins. A further mechanism
is that younger people at high risk of developing diabetes
are accurately targeted for statin treatment, which in
conjunction with the former effect would attenuate the
expected age gradient. The progression of pre-diabetes
to T2DM has been extensively studied and both higher
BMI, weight gain, blood pressure, younger age and triglyc-
erides have been identified as predictors of diabetes devel-
opment [47-49]. The increased risk of developing T2DM
with longer statin use is difficult to separate from the
effect of other predictors of worsening beta cell function/
decreased insulin sensitivity over time. T2DM is a multi-
factorial disease, with complex interactions between vari-
ous environmental, behavioral and genetic factors, making
the contribution of each single factor difficult to assess.
Limitations and strengths
A major strength of this study was the large cohort size
and the potential for long term follow-up, giving sufficient
power to analyze comparatively rare and long latency
outcomes such as T2DM. Additionally, our study was
based on routine clinical data representative of the
general UK population, and therefore better reflects the
nature and frequency of events experienced in general
clinical practice.
Despite these positive aspects, observational studies
have limitations, notably bias and unmeasured confound-
ing. Confounding was reduced by adjustment for a wide
range of potential confounding factors and by the use of
propensity scores and matching. Propensity score analysis
can successfully account for much confounding by indica-
tion, but residual confounding is possible due to risk fac-
tors that have not been considered in the analyses, or to
potential changes in risk factors during follow up.
Prescription data were prospectively recorded prior to
the outcomes, with no potential for recall bias. Misclassifi-
cation of exposure is possible because low dose of statins
may be purchased over the counter. However, it is likely
that most prescriptions are issued in primary care, espe-
cially among people aged 60+ and those with comorbidi-
ties, who will have free prescriptions. A prescription does
not necessarily mean that a patient has taken a drug and
non-adherence to treatment is likely to affect any study.
Although adherence with statins could not be ascertained,
85% and 83% of statins users had at least one statin pre-
scription between 12 and 24 months of follow up (year 2)
and between 24 and 36 months (year 3), respectively. We
believe that repeat prescribing for statins is likely to
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represent regular and genuine drug use in most cases.
Misclassification of the outcome is possible, since we did
not have information on the diagnostic criteria, although
validation studies undertaken using GPRD data have
shown high levels of accuracy [23-27], and any such mis-
classification is likely to be non-differential with respect to
exposure, expected to lead to a reduction in power only.
Misclassification of BMI due to missing data is possible.
Although we had no information on the reasons for miss-
ing BMI, our findings didn’t change when our analysis
was restricted to patients with low or normal BMI levels.
The marked increased risk of T2DM observed in the
first year could be explained by detection bias, as people
are likely to start a statin during a period of time when
their health is of concern; they will tend to see their
general practitioner more often and may be more likely
to have a blood glucose test, thereby increasing the
likelihood of detection of diabetes. Ascertainment bias
might also partly account for the increased risk observed,
particularly in the first year of starting treatment, because
people prescribed statins may consult their general practi-
tioner more often and have more blood tests, thereby
increasing the likelihood of detection of abnormal blood
glucose levels.
We also recognized the potential for survival bias in our
study, as the mean follow up time was different between
groups (5.43 years for statin users and 3.89 years for
nonusers) and statin users were slightly less likely to die
(10.79%) compared to the nonusers group (11.66%). This
means that statin nonusers might die earlier and, conse-
quently, don’t have the same probability of developing
T2DM as the statin users who remain under follow up.
This could bias the estimate of effect for statin use away
from the null.
Implications for clinical practice and future research
Our observational study provides evidence that statin use
is associated with an increased risk of T2DM develop-
ment, which increases with longer duration of use and
higher baseline BMI levels. The increased risk was greater
than that observed in randomized trials of statin therapy.
The increased risk was less marked among people with
diagnosed hypertension or cardiovascular disease. The
Cholesterol Treatment Trialists’ collaboration has pro-
vided strong evidence of reductions in major vascular
events from statins across all risk categories, with rates
in diabetic populations comparable with those without
diabetes [3-6]. However, in a recent study using the
Taiwan National Health Insurance Research Database,
incident diabetes after statin therapy was associated
with an increased risk of major cardiovascular events
and in-hospital death compared with the nondiabetic
controls, although not in the high-risk and secondary
prevention cohorts [15]. Based on these findings, the
authors suggest caution in extending statin therapy to
low-risk individuals, as has been advocated recently [15].
The consequences of statin-induced T2DM deserve
more attention. Particularly, since findings from a recent
cohort of 3.8 million general population patients showed
substantive overuse of statins in low CVD risk and
underuse in high CVD risk [50]. Once a patient develops
diabetes, although their cardiovascular risk doubles,
statins prevent cardiovascular events. Among a low risk
population (5-year cardiovascular risk less than 10%), the
Cholesterol Treatment Trialists’ collaboration estimated
that 11 major vascular events would be avoided per 1000
individuals treated for 5 years [5]. For longer periods of
treatment both the increased risk of T2DM and the
protective effect against vascular events increased. Further
research should explore the mechanism underlying statin
induced T2DM.
Conclusion
Statin use is associated with an increased risk of T2DM,
which increases with longer duration of use and higher
baseline BMI levels. Our results suggest that the relative
risk is higher among people without diagnosed hyper-
tension or cardiovascular disease.
These findings should be interpreted with caution as
observational studies are subject to residual confounding
by indication and other biases that cannot be ruled out.
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